Ultragenyx

Ultragenyx is a biotechnology and pharmaceutical company founded in 2010 in the United States. The company is dedicated to advancing innovative medicines for rare and ultrarare diseases, with a focus on delivering transformative therapies for diseases that have previously been untreated. Ultragenyx has built a diverse portfolio of approved therapies and products aimed at diseases with a high unmet medical need, reflecting their commitment to addressing challenging medical conditions. The company's inclusive culture is highlighted, emphasizing the value and respect placed on its people and the rare disease community. Ultragenyx's recent post-IPO equity investment of $350.00M on 13 June 2024 underscores the confidence investors have in the company's mission and progress. The CEO and President, Emil D. Kakkis, M.D., Ph.D., emphasizes the company's dedication to doing the right things for patients both during development and commercialization, positioning Ultragenyx as a leader in advancing therapies for rare diseases. The company fosters a dynamic work environment where team members are encouraged to share new ideas and unlock possibilities, reflecting a commitment to growth and fulfillment. Ultragenyx's commitment to bringing novel products to those living with rare and ultrarare diseases, combined with its recent substantial investment, positions the company as a significant player in the pharmaceutical industry. Their focus on delivering on the promise of transformative therapies in a meaningful way for rare disease communities and inclusive, supportive work environment sets Ultragenyx apart in the biotechnology and pharmaceutical sectors.